Opendata, web and dolomites

VOGAS SIGNED

Screening of Gastric Cancer via Breath volatile organic compounds by Hybrid Sensing Approach

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 VOGAS project word cloud

Explore the words cloud of the VOGAS project. It provides you a very rough idea of what is the project "VOGAS" about.

spectrometry    chances    voc    metaplasia    nanoparticles    panels    confounding    clinical    cured    parallel    organic    tissue    vital    combine    gastric    chile    flora    individuals    stage    components    optimized    prototypes    patients    expertise    electronic    validated    intestinal    spectroscopic    enrolled    members    america    sensors    data    concentration    mass    portable    techniques    building    nose    acquired    mechanisms    ukraine    dimensional    coupled    cancer    screening    schemes    exhaled    international    mid    gold    headspace    breath    good    tool    geographical    analyser    infrared    first    composition    compounds    countries    metal    colombia    vocs    eastern    gc    obtaining    device    detecting    ms    disease    bacterial    infection    human    orthogonal    utilizing    burden    latin    atrophy    volatile    diagnosed    american    precancerous    dysplasia    origin    chromatography    lines    lesions    competences    latvia    compact    cell    oxide    previously    analytical    brazil    lack    invasive    collaborations    gas    pylori   

Project "VOGAS" data sheet

The following table provides information about the project.

Coordinator
TECHNION - ISRAEL INSTITUTE OF TECHNOLOGY 

Organization address
address: SENATE BUILDING TECHNION CITY
city: HAIFA
postcode: 32000
website: www.technion.ac.il

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 3˙781˙179 €
 EC max contribution 3˙781˙179 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SC1-2018-Single-Stage-RTD
 Funding Scheme RIA
 Starting year 2019
 Duration (year-month-day) from 2019-01-01   to  2021-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    TECHNION - ISRAEL INSTITUTE OF TECHNOLOGY IL (HAIFA) coordinator 650˙363.00
2    LATVIJAS UNIVERSITATE LV (RIGA) participant 510˙000.00
3    UNIVERSITAET INNSBRUCK AT (INNSBRUCK) participant 395˙535.00
4    UNIVERSITAET ULM DE (ULM) participant 385˙000.00
5    JLM INNOVATION GMBH DE (TUEBINGEN) participant 375˙000.00
6    Teknologian tutkimuskeskus VTT Oy FI (Espoo) participant 358˙875.00
7    UPPSALA UNIVERSITET SE (UPPSALA) participant 253˙727.00
8    UNIVERSIDAD DE PAMPLONA CO (PAMPLONA) participant 250˙625.00
9    NATIONAL CANCER INSTITUTE UA (KIYV) participant 210˙000.00
10    HOSPITAL UNIVERSITARIO SAN IGNACIO CO (BOGOTA) participant 209˙984.00
11    PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE CL (SANTIAGO) participant 182˙068.00
12    FUNDACAO ANTONIO PRUDENTE BR (SAO PAULO) participant 0.00

Map

 Project objective

Gastric cancer has good chances to be cured if diagnosed at an early stage; currently, there is lack of a reliable non-invasive screening tool. Eastern Europe and Latin America are among the geographical areas with high burden of the disease.

This project is aiming at developing a non-invasive gastric cancer screening tool by detecting characteristic panels of volatile organic compounds (VOCs). The mechanisms of VOC origin and their composition in gastric cancer patients will be addressed via headspace analysis of cancer tissue, cell-lines, and bacterial flora; VOCs identified during this analysis will be compared to the compounds present in human breath, both via gas chromatography coupled to mass spectrometry (GC-MS).

Based on this data, a new type of breath analyser will be developed and validated building upon previously acquired expertise of the consortium members. Specifically, the exhaled breath analyser will combine electronic nose concepts utilizing gold nanoparticles and metal oxide sensors with orthogonal mid-infrared spectroscopic techniques for obtaining multi-dimensional analytical data sets; furthermore, compact pre-concentration schemes will be evaluated. All components will be integrated into several prototypes of portable and optimized devices.

The clinical studies will be conducted in parallel in European (Latvia, Ukraine) and Latin American (Colombia, Brazil, Chile) countries with high disease burden. Patients with gastric cancer and individuals with and without precancerous lesions (dysplasia, atrophy, intestinal metaplasia) will be enrolled. The role of confounding factors including H.pylori infection will be addressed.

As the main result, we expect to provide the first reliable non-invasive gastric cancer screening device based on exhaled breath analysis concepts for future large-scale implementation. The development of according research competences and international collaborations therefore is the most vital component of this project.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "VOGAS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "VOGAS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

VANGUARD (2020)

New Generation Cell Therapy: Bioartificial Pancreas to Cure Type 1 Diabetes

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More  

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination

Read More